Key Developments: Celgene Corp (CELG.O)

CELG.O on Nasdaq

22 Oct 2014
Price Change (% chg)

$-0.21 (-0.22%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Search Stocks

Latest Key Developments (Source: Significant Developments)

Celgene Corp reaffirms FY 2017 revenue guidance - Conference Call
Wednesday, 11 Jun 2014 01:00pm EDT 

Celgene Corp:Expects FY 2017 revenue of $13 billion to $14 billion overall.FY 2017 revenue of $13 billion - Thomson Reuters I/B/E/S.  Full Article

Celgene Corp's subsidiary updates phase III clinical trials of OTEZLA
Wednesday, 11 Jun 2014 07:30am EDT 

Celgene Corp:Says a subsidiary Celgene International Sarl, results of additional analyses from the phase III clinical trials of OTEZLA, the company's oral, selective inhibitor of phosphodiesterase 4 (PDE4).These included long-term (52-week) analyses from the PALACE 1, 2 and 3 trials of the impact of OTEZLA on psoriatic arthritis disease activity, safety and tolerability, in addition to a separate 16-week work productivity analysis from PALACE 1.The findings were presented at the European League Against Rheumatism Annual Congress (EULAR 2014) in Paris, France.  Full Article

Celgene announces appointment of Chief Financial Officer
Thursday, 22 May 2014 06:00am EDT 

Celgene Corp:Appoints Peter Kellogg as Executive Vice President, Chief Financial Officer.  Full Article

Celgene Corp gives FY 2017 revenue guidance in line with analysts' estimates - Conference Call
Monday, 19 May 2014 01:30pm EDT 

Celgene Corp:Says for FY 2017 it expect $13 billion to $14 billion in sales by that period of time.FY 2017 revenue of $13.14 billion - Thomson Reuters I/B/E/S.  Full Article

Celgene announces public offering of Senior Notes due 2019, 2024 and 2044 - Form 8-K
Wednesday, 7 May 2014 02:18pm EDT 

Celgene Corp:Announces underwritten public offering of $500 mln aggregate principal amount of 2.250pct Senior Notes due 2019, $1 bln aggregate principal amount of 3.625pct Senior Notes due 2024 and $1 bln aggregate principal amount of 4.625pct Senior Notes due 2044.Intends to use the net proceeds for general corporate purposes.Merrill Lynch, Pierce, Fenner & Smith Incorporated, Credit Suisse Securities (USA) LLC, Goldman, Sachs & Co. and Morgan Stanley & Co. LLC acts as underwriters.  Full Article

Celgene Corp reaffirms long term outlook - Conference Call
Wednesday, 7 May 2014 10:10am EDT 

Celgene Corp:Says looking out to FY 2017 it estimated top line all in for franchises of $13 -$14 bln with a bottom line opportunity of up to $15 in EPS.FY 2017 revenue of $13 bln, EPS of $15 - Thomson Reuters I/B/E/S.  Full Article

Celgene Corp announces offering of senior unsecured notes
Tuesday, 6 May 2014 08:30am EDT 

Celgene Corp:Intention to offer senior unsecured notes under shelf registration statement on Form S-3 on file with Securities and Exchange Commission.Interest rate, the maturity dates and other key terms of the offering are to be determined at time of pricing.Expects to use net proceeds for general corporate purposes.  Full Article

Celgene Corp affirms FY 2014 guidance
Thursday, 24 Apr 2014 07:34am EDT 

Celgene Corp:Affirms FY 2014 adjusted diluted EPS guidance and total revenue guidance.Expects FY 2014 total revenue to be about $7.500 mln.Expects FY 2014 adjusted diluted EPS to be in the range of $7.00 to $7.20.Expects FY 2014 GAAP diluted EPS to be in the range of $4.94 to $5.18.  Full Article

Celgene Corporation acquires Late-Stage Product for Crohn's Disease and Other Gastrointestinal Disorders
Thursday, 24 Apr 2014 07:30am EDT 

Celgene Corporation:Enters into global license agreement with Nogra Pharma Limited to develop and commercialize GED-0301, an oral antisense DNA oligonucleotide targeting Smad7 mRNA for treatment of moderate-to-severe Crohn's disease and other indications.Nogra Pharma Limited will receive upfront payment of $710 mln, regulatory, development and net sales milestone payments and tiered royalties.Aggregate payments for regulatory and development milestones could potentially be $815 mln for multiple indications.  Full Article

Celgene Corp announces expansive multi-year strategic alliance with FORMA Therapeutics
Tuesday, 1 Apr 2014 07:30am EDT 

FORMA Therapeutics:Says a second strategic collaboration and option agreement with Celgene Corp.New collaboration will enable FORMA to extend its capabilities across broad areas of chemistry and biology.FORMA received an upfront cash payment of $225 million, and the parties entered into a collaboration with a term of 3 ½ years.  Full Article

UPDATE 1-Celgene 3rd quarter profit up 37 pct; edges above forecast

Oct 23 - Celgene Corp on Thursday reported third quarter profit rose 37 percent on a double-digit jump in sales of its flagship multiple myeloma medicine Revlimid and strong demand for its other drugs, and the U.S. biotechnology company raised its full-year earnings forecast by 5 cents.

Search Stocks